Generic Sklice Availability
SKLICE (ivermectin - lotion;topical)
Manufacturer: SANOFI PASTEUR INC
Approval date: February 7, 2012
Strength(s): 0.5% [RLD]
Has a generic version of Sklice been approved?
No. There is currently no therapeutically equivalent version of Sklice available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sklice. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Topical preparation and therapy for head lice
Issued: August 15, 2000
Inventor(s): Burkhart; Craig G. & Burkhart; Craig N.
A topical preparation for applying to scalp hair for the treatment of head lice, the topical preparation including a killing agent effective to kill the head lice, a lipophilic carrier for the killing agent, the carrier including a surfactant effective to allow the topical preparation to be washed out of the hair, and the carrier having a viscosity within a range of from about 10,000 centipoise to about 85,000 centipoise at 21.degree. C. A topical therapy for head lice includes applying the topical preparation to dry scalp hair infested with head lice, and leaving the topical preparation on the hair at least about 15 minutes. The therapy preferably includes applying a second application of the topical preparation about 6-10 days after the first application.Patent expiration dates:
- May 22, 2018✓
- May 22, 2018
Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
Issued: July 29, 2014
Assignee(s): Sanofi-Topaz, Inc.
An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.Patent expiration dates:
- October 12, 2027✓
- October 12, 2027
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 7, 2015 -
More about Sklice (ivermectin topical)
- Other brands: Soolantra
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|